Association of CYP2D6 100 C > T and 2850 C > T Polymorphisms with Generalized Tonic Clonic Seizures Among Indians

Overview

Journal J Neural Transm (Vienna)

Specialties Neurology
Physiology

Date 2006 Jul 13

PMID 16835697

Citations 3

Authors

C C Soundararajan

A Adhin

M Tripathi

H K Prasad

S Jain

S Vivekanandhan

Affiliations

Soon will be listed here.

Abstract

Multiple avenues of research have provided evidence for the role of genetic and environmental factors in epilepsy. Previous studies indicated an association of debrisoquine hydroxylase (CYP2D6) with susceptibility to epilepsy. In this study, association of CYP2D6 100C > T and 2850C > T polymorphisms with generalized tonic clonic seizures (GTCS) among Indians has been analysed using case-control approach. A significant association of 2850C > T (P = 0.015) has been observed. Comparison between phenytoin toxic and others among patients showed no association of these polymorphisms with phenytoin toxicity.

Citing Articles

Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective.

Umamaheswaran G, Kumar D, Adithan C Indian J Med Res. 2014; 139(1):27-65.

PMID: 24604039 PMC: 3994740.

Pharmacogenetics and gender association with psychotic episodes on nortriptyline lower doses: patient cases.

Piatkov I, Jones T ISRN Pharm. 2012; 2011:805983.

PMID: 22389859 PMC: 3263719. DOI: 10.5402/2011/805983.

Cytochrome P450 2D6.

Owen R, Sangkuhl K, Klein T, Altman R Pharmacogenet Genomics. 2009; 19(7):559-62.

PMID: 19512959 PMC: 4373606. DOI: 10.1097/FPC.0b013e32832e0e97.

References

Alvan G, Bechtel P, Iselius L, Gundert-Remy U . Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol. 1990; 39(6):533-7. DOI: 10.1007/BF00316090. View

Wolf C, Smith G . Cytochrome P450 CYP2D6. IARC Sci Publ. 1999; (148):209-29. View

Borlak J, Harsany V, Schneble H, Haegele K . pNAT and CYP2D6 gene polymorphism in epileptic patients. Biochem Pharmacol. 1994; 48(9):1717-20. DOI: 10.1016/0006-2952(94)90456-1. View

Roh H, Dahl M, Johansson I, Ingelman-Sundberg M, CHA Y, Bertilsson L . Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics. 1996; 6(5):441-7. DOI: 10.1097/00008571-199610000-00008. View

Lamba V, Lamba J, Dilawari J, Kohli K . Genetic polymorphism of CYP2D6 in North Indian subjects. Eur J Clin Pharmacol. 1999; 54(9-10):787-91. DOI: 10.1007/s002280050552. View

Sridharan R, Murthy B . Prevalence and pattern of epilepsy in India. Epilepsia. 1999; 40(5):631-6. DOI: 10.1111/j.1528-1157.1999.tb05566.x. View

Lennard M . Genetically determined adverse drug reactions involving metabolism. Drug Saf. 1993; 9(1):60-77. DOI: 10.2165/00002018-199309010-00006. View

Tsuneoka Y, Matsuo Y, Iwahashi K, Takeuchi H, Ichikawa Y . A novel cytochrome P-450IID6 mutant gene associated with Parkinson's disease. J Biochem. 1993; 114(2):263-6. DOI: 10.1093/oxfordjournals.jbchem.a124164. View

Berkovic S, Howell R, Hay D, Hopper J . Epilepsies in twins: genetics of the major epilepsy syndromes. Ann Neurol. 1998; 43(4):435-45. DOI: 10.1002/ana.410430405. View

10.

Ray B, Bhattacharya S, Kundu T, Prasad Saha S, Das S . Epidemiology of epilepsy--Indian perspective. J Indian Med Assoc. 2002; 100(5):322-6. View

11.

Spear B . Pharmacogenetics and antiepileptic drugs. Epilepsia. 2002; 42 Suppl 5:31-4. DOI: 10.1046/j.1528-1157.2001.0420s5031.x. View

12.

Komatsu T, Yamazaki H, Asahi S, Gillam E, Guengerich F, Nakajima M . Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4. Drug Metab Dispos. 2000; 28(11):1361-8. View

13.

Dahl M, Yue Q, Roh H, Johansson I, Sawe J, Sjoqvist F . Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics. 1995; 5(3):159-64. DOI: 10.1097/00008571-199506000-00004. View

14.

Iwahashi K, Suwaki H, Matsuo Y, Ichikawa Y, Hosokawa K . Correspondence of increased debrisoquine 4-monooxygenase activity with seizure-susceptibility in Mongolian gerbils. J Neurol Sci. 1994; 121(1):18-21. DOI: 10.1016/0022-510x(94)90150-3. View

15.

Ho S, Kung M, Li L, Lauder I, Ramsden D . Cytochrome P4502D6 (debrisoquine 4-hydroxylase) and Parkinson's disease in Chinese and Caucasians. Eur J Neurol. 1999; 6(3):323-9. DOI: 10.1046/j.1468-1331.1999.630323.x. View

16.

Meyer U, Zanger U . Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol. 1997; 37:269-96. DOI: 10.1146/annurev.pharmtox.37.1.269. View

17.

Marez D, Legrand M, Sabbagh N, Lo Guidice J, Spire C, Lafitte J . Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 1997; 7(3):193-202. DOI: 10.1097/00008571-199706000-00004. View

18.

Ottman R, Annegers J, Risch N, Hauser W, Susser M . Relations of genetic and environmental factors in the etiology of epilepsy. Ann Neurol. 1996; 39(4):442-9. PMC: 2737460. DOI: 10.1002/ana.410390406. View

19.

Abraham B, Adithan C, Mohanasundaram J, Shashindran C, Koumaravelou K, Asad M . Genetic polymorphism of CYP2D6 in Tamil population. Eur J Clin Pharmacol. 2001; 56(11):849-50. DOI: 10.1007/s002280000231. View

20.

Wilkinson G . Drug metabolism and variability among patients in drug response. N Engl J Med. 2005; 352(21):2211-21. DOI: 10.1056/NEJMra032424. View